Illumina, Inc.
ILMN Healthcare Diagnostics & Research
Illumina, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 0.66% from fiscal 2024. In the quarter to June 2026, revenue grew 9.44%, EPS fell 8.05%, free cash flow fell 18.3% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow ILMN
Illumina, Inc. (ILMN) Revenue
Illumina, Inc.'s revenue for fiscal 2025 was $4.3B, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $4.5B. Over the past ten years it has ranged from $2.2B (fiscal 2015) to $4.6B (fiscal 2022); the current reading is higher than 64% of that period. Revenue has fallen for 3 consecutive fiscal years. Illumina, Inc. ranks 10th of 50 Diagnostics & Research companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $4.3B | (0.66%) |
| FY2024 | $4.4B | (2.93%) |
| FY2023 | $4.5B | (1.75%) |
| FY2022 | $4.6B | 1.28% |
| FY2021 | $4.5B | 39.73% |
| FY2020 | $3.2B | (8.58%) |
| FY2019 | $3.5B | 6.30% |
| FY2018 | $3.3B | 21.11% |
| FY2017 | $2.8B | 14.76% |
| FY2016 | $2.4B | 8.02% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $1.2B | 6.23% |
| Mar 2026 | $1.1B | (5.87%) |
| Dec 2025 | $1.2B | 6.92% |
| Sep 2025 | $1.1B | 2.36% |
| 42 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| IQV IQVIA Holdings Inc. compare | $17.0B |
| LH Labcorp Holdings Inc. compare | $14.3B |
| DGX Quest Diagnostics Incorporated compare | $11.6B |
| A Agilent Technologies, Inc. compare | $7.4B |
| WAT Waters Corporation compare | $4.6B |
| IDXX IDEXX Laboratories, Inc. compare | $4.6B |
| ILMN Illumina, Inc. | $4.5B |
| MTD Mettler-Toledo International, Inc. compare | $4.1B |
| NTRA Natera, Inc. compare | $2.7B |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on ILMN
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement